LONDON, Aug. 01, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017
Time: 3:05 PM EDT
Location: New York, NY
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / James White | ||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||
| ICR, Inc. (US Media and Investor enquiries) | ||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



